anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To obtain an ameliorant for visual function disorder useful for ameliorating visual function disorders and a protective agent for optic nerve cells useful for protecting optic nerve cells.  <P>SOLUTION: The ameliorant for visual function disorder and the protective agent for optic nerve cells each comprises a propolis extract or a compound contained in a propolis original lump as an active ingredient. The active ingredient is preferably an extract of propolis with water, an alcohol extract or a water-containing alcohol extract. The ameliorant for visual function disorders ameliorates visual function disorders especially caused by reduction in function of optic nerve cells. The protective agent for optic nerve cells exhibits protection action especially on retinal ganglion cells and is useful for treating or preventing eye diseases. Retinal diseases such as retinal vessel occlusion, diabetic retinopathy, ischemic optic neuropathy, macular degeneration, pigmentary degeneration of the retina, Leber's disease, glaucoma, etc., may be cited as the eye diseases.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
To analyze the differential expression genes of polycystic ovary syndrome (PCOS), clarify their functions and pathways, as well as the protein-protein interaction network, identify HUB genes, and explore the pathological mechanism. PCOS microarray datasets were screened from the GEO database. Common differentially expressed genes (co-DEGs) were obtained using GEO2R and Venn analysis. Enrichment and pathway analyses were conducted using the DAVID online tool, with results presented in bubble charts. Protein-protein interaction analysis was performed using the STRING tool. HUB genes were identified using Cytoscape software and further interpreted with the assistance of the GeneCards database. A total of two sets of co-DEGs (108 and 102), key proteins (15 and 55), and hub genes (10 and 10) were obtained. The co-DEGs: (1) regulated inflammatory responses and extracellular matrix, TNF, and IL-17 signaling pathways; (2) regulated ribosomes and protein translation, ribosome and immune pathways. The key proteins: (1) regulated inflammation, immunity, transcription, matrix metabolism, proliferation/differentiation, energy, and repair; (2) regulated ubiquitination, enzymes, companion proteins, respiratory chain components, and fusion proteins. The Hub genes: (1) encoded transcription factors and cytokines, playing vital roles in development and proliferation; (2) encoded ribosomes and protein synthesis, influencing hormone and protein synthesis, associated with development and infertility. The dysregulated expression of inflammation and protein synthesis genes in PCOS may be the key mechanism underlying its onset and progression.
The invention discloses an automatic cylinder locking apparatus for a fruit and vegetable carbon dioxide dehydrating cylinder. The invention relates to a dehydrating cylinder used in a carbon dioxide dehydrating process of fruits, vegetables, and Chinese herbal medicines. According to the invention, a plurality of pin columns 6 are arranged between a clamping slot 2-1 of a cylinder body 2 and a jaw 3-1 of a cylinder cap 3, such that cylinder locking force is improved, and safety is ensured. Inner ends of the pin columns 6 are inserted in pinholes of the clamping slot 2-1 and the jaw 3-1. Outer ends of the pin columns 6 are connected to a driver 5, which is arranged on a supporting seat 4. The supporting seat 4 is arranged on the cylinder body 2. The driver 5 is a hydraulic cylinder or a pneumatic cylinder. The hydraulic cylinder or the pneumatic cylinder is connected to an external hydraulic station or an external pneumatic station through a controlling valve and pipe lines. The driver 5 also can be a solenoid valve, which is connected to an external controlling system through conductors.
If an intubated patient is suspected of having an ICU-acquired HAP/VAP during the aggressive period, antimicrobials should be initiated immediately after quantitative or semi-quantitative endobronchial cultures are sent regardless of clinical status. This will include patients who, as determined by the attending intensivist, are in sepsis or septic shock. If, after 72 hours, cultures and other clinical data do not point to a pneumonia, the antimicrobials should be stopped in the absence of another source of infection.
BACKGROUND: The "gold standard" marker for freezing of gait severity is percentage of time spent with freezing observed through video analysis.
OBJECTIVE: This study examined inter- and intra-rater reliability and variability of physiotherapists rating freezing of gait severity through video analysis and explored the effects of experience.
METHODS: Thirty physiotherapists rated 14 videos of Timed Up and Go performance by people with Parkinson's and gait freezing. Ten videos were unique, while four were repeated. Freezing frequency, total duration, and percentage of time spent with freezing were computed. Reliability and variability were estimated using ICC (2,1) and mean absolute differences. Between-group differences were calculated with the one-way ANOVA.
RESULTS: Inter- and intra-rater reliability ranged from moderate to good (ICC: inter-rater frequency = 0.63, duration = 0.78, percentage = 0.50; intra-rater frequency = 0.84, duration = 0.89, percentage = 0.50). Variability for freezing frequency was two episodes. Inter- and intra-rater variability for total freezing duration was 18.8 and 12.3  seconds, respectively. For percentage of time spent with freezing, this was 15.2% and 13.5%. Physiotherapy experience had no effect.
CONCLUSION: Physiotherapists demonstrated sufficient reliability, but variability was large enough to cause changes in severity classifications on existing rating scales. Percentage of time spent with freezing was the least reliable marker, supporting the use of freezing frequency or total duration instead.
The invention relates to a traditional Chinese medicine composition for treating anal condyloma acuminata. The composition is prepared from solidago decurrens, herba portulacae, cortex dictamni, scouring rush, radix isatidis, pepper, salvia miltiorrhiza, peach kernels, safflower carthamus, brucea javanica, calcined oyster shell, flos chrysanthemi indici, radix sophorae flavescentis, pomegranate bark, coix seeds, rhizoma cyperi and cyrtomium fortunei. The invention further discloses a preparation method and application of the traditional Chinese medicine composition. The preparation method has the advantage of simple medicine preparation process, and is suitable for industrial production. Traditional Chinese medicine powder prepared from the traditional Chinese medicine composition for treating anal condyloma acuminata is convenient to carry and store, is convenient to use, does not need decoction and has two functions. The traditional Chinese medicine composition has the effects of clearing heat, removing toxicity, eliminating phlegm and removing stasis and wart, can achieve the focus, has the local curative effect superior to internal administration, and has specific and powerful medicinal effect and quick response.
Morus alba is invaluable member of the plant kingdom belonging to the family Moraceae and the genus Morus. It is extensively cultivated for leaf yield in sericulture. Morus alba have long been used in traditional medicine to improve eyesight, lower blood pressure, prevent diabetes, protect the liver, strengthen joints and treat fever. In particular, few studies on mulberry fruits have reported its biological activities such as antioxidative and anti-inflammatory activities. Even the root bark of has been traditionally used in Asian countries for medicinal purposes due to its anti-inflammatory, hypoglycemic, antibacterial activities. LD50 of extracts of Morus Alba leaves was found to be above 2000 mg/kg which is safe to be used in human beings. Therefore, in the present study the Morus alba leaves has been used in the gel preparation and its effectiveness is assessed against periodontal microorganisms.
Participants with body weight (BW)\<60 kg receive Lenvatinib 8 mg orally once daily on a 21 or 42 day cycle. It is taken 0-4 hours after completion of pembrolizumabd administration in the clinic on cycle 1 day 1(C1D1), C2D1, C3D1, etc. Taken at home on all other days.
Participants will receive STAV-loaded cells for a total of 5 doses on Days 3, 17, 31, 45 and 59. Participants will also receive up to 4 doses of dendritic vaccine on Days 10, 17, 24 and 31.
Eligible subjects will be randomized in sequence A/B/C and will receive A: single tablet of paroxetine 12.5 milligrams, B: single tablet of paroxetine 25 milligrams and C: two tablets of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
The invention discloses application of nicotinamide mononucleotide on a product for preventing spermatogenesis dysfunction of obese men, and the product is a spermatogenesis dysfunction product of obese men testes. Provides a new application of NMN in improving the testicular spermatogenesis dysfunction of obese mice, and provides a new treatment strategy and a new drug target for intervening and controlling the testicular spermatogenesis dysfunction induced by obesity and improving the fertility of obese men. The supplement of NMN to obese mice can significantly reduce the body weight, fat weight and serum lipid metabolism hormone levels of obese mice. After the obese mice are supplemented with NMN, the shapes of testis and epididymis, the diameter and the area of a seminiferous tubule can be improved, and the number of sperms, the sperm motility and the sperm quality can be improved. Obese mice significantly improved the support cell morphology and function after NMN supplementation. Supplementation of NMN in obese mice also ameliorates spermatogenic dysfunction by deacetylation modification of the supportive cellular glycolytic pathway.
Patients randomized to the control group will be sent the post-test measures suitably modified to reflect the fact that they did not participate in the conjoint analysis program. Four weeks after the post-test measures are completed, a staff member will call the subject to complete a 10 minute follow-up questionnaire to assess if any changes in treatment have occurred and to take further measurements (same measurements given to treatment group).
Patients will be treated with 14 days of GM-CSF self-administered subcutaneously daily for 14 days in a dose of 125 µg/m2 beginning on the day of enrollment. Patients will be instructed in the self-administration of GM-CSF and after they have demonstrated competency with the procedure, they will self-administer the treatment at home. Patients will undergo surgery within 1 day to 5 days after cessation of the GM-CSF therapy.
MK-8266 TID (Panel D), 2.4 mg (0.8 mg q6hr), or as matching placebo TID. Panel D was completed prior to initiation of Panel E.
OBJECTIVES: I. Compare event free survival after total body irradiation (TBI) plus busulfan versus TBI plus cyclophosphamide followed by allogeneic peripheral blood stem cell transplantation in patients with advanced myelodysplastic syndrome (MDS) or MDS related acute myeloid leukemia. II. Determine the distribution of pharmacokinetic parameters for busulfan in those patients randomized to the busulfan treatment arm. III. Investigate the prognostic significance for event free survival of prior history of red cell transfusions, cytogenetic pattern, and of functional drug resistance at diagnosis in these patients. IV. Estimate the frequencies of cytogenetic and genetic changes during disease progression in these patients.

OUTLINE: This a randomized, multicenter study. Patients are stratified according to age (40 and under vs 41-55) and diagnosis and International Prognostic Scoring System (IPSS) risk group (myelodysplastic syndrome (MDS)/IPSS - intermediate 1 vs MDS/IPSS - intermediate 2 vs MDS/IPSS high risk vs MDS related acute myeloid leukemia). Patients are randomized to one of two treatment arms. Arm I: Patients receive busulfan IV over 2 hours every 6 hours on days -7 to -4 for a total of 16 doses. Arm II: Patients receive cyclophosphamide IV over 2 hours on days -5 and -4. Patients receive total body irradiation (TBI) twice a day on days -3 to -1; peripheral blood stem cell transplantation from genotypically HLA identical sibling on day 0; cyclosporine IV every 12 hours on days -1 to 60, and then tapering in the absence of graft versus host disease; and methotrexate IV on days 1, 3, 6, and 11. Patients are followed every 6 months for 5 years.

PROJECTED ACCRUAL: A total of 240 patients (120 per treatment arm) will be accrued for this study over 5 years.
BACKGROUND: The monocyte-lymphocyte ratio (MLR) is a hematological test parameter that reflects the status of both monocytes and lymphocytes as inflammatory cells. This study aims to investigate the relationship between MLR and carotid intraplaque neovascularization (IPN) in patients with asymptomatic carotid stenosis.
METHODS: We performed the Angio Planewave Ultrasensitive (AngioPLUS) screening for patients with carotid plaques. The carotid plaque stability was evaluated by semiquantitative visual grading of carotid IPN. Binary logistic regression models were performed to determine the associations between different clinical and laboratory indicators and the presence of high IPN.
RESULTS: A total of 160 patients were eventually enrolled with 99 in the low IPN group (Scores 0-1) and 61 in the high IPN group (Score 2). Univariate logistic regression showed that age, monocytes, lymphocytes, glycated hemoglobin (HbA1c), fibrinogen, d-dimmer, and MLR were significantly associated with the presence of high IPN (all p < 0.05). Multivariate logistic regression models showed that MLR was significantly associated with the presence of high IPN after adjusting for other covariates. An MLR value of 32.9 was the optimal cutoff value to differentiate high and low IPN. High MLR was also significantly correlated with the presence of high IPN (odds ratio [OR] = 4.08, 95% confidence interval [CI]: 1.69-9.88, p = 0.002) when included in the above multivariate logistic regression model.
CONCLUSION: Elevated MLR is closely associated with the presence of high IPN and may serve as a surrogate biomarker for carotid IPN.
Oral delivery of proteins faces challenges due to the harsh conditions of the gastrointestinal (GI) tract, including gastric acid and intestinal enzyme degradation. Permeation enhancers are limited in their ability to deliver proteins with high molecular weight and can potentially cause toxicity by opening tight junctions. To overcome these challenges, we propose the use of montmorillonite (MMT) as an adjuvant that possesses both inflammation-oriented abilities and the ability to regulate gut microbiota. This adjuvant can be used as a universal protein oral delivery technology by fusing with advantageous binding amino acid sequences. We demonstrated that anti-TNF-α nanobody (VII) can be intercalated into the MMT interlayer space. The carboxylate groups (-COOH) of aspartic acid (D) and glutamic acid (E) interact with the MMT surface through electrostatic interactions with sodium ions (Na+). The amino groups (NH2) of asparagine (N) and glutamine (Q) are primarily attracted to the MMT layers through hydrogen bonding with oxygen atoms on the surface. This binding mechanism protects VII from degradation and ensures its release in the intestinal tract, as well as retaining biological activity, leading to significantly enhanced therapeutic effects on colitis. Furthermore, VII@MMT increases the abundance of short-chain fatty acids (SCFAs)-producing strains, including Clostridia, Prevotellaceae, Alloprevotella, Oscillospiraceae, Clostridia_vadinBB60_group, and Ruminococcaceae, therefore enhance the production of SCFAs and butyrate, inducing regulatory T cells (Tregs) production to modulate local and systemic immune homeostasis. Overall, the MMT adjuvant provides a promising universal strategy for protein oral delivery by rational designed protein.
Families will receive the FCU4Health program 3 times annually in a health maintenance model. The FCU4Health coordinator reviews the assessment results with the parents, using motivational interviewing strategies to create a tailored plan to address family needs. This plan may include referrals to community resources or parenting modules that focus on family management.
Eligible patients will receive cabozantinib as a tablet, orally daily. One cycle is defined as 28 days. Myeloma response will be assessed by IMWG criteria after each cycle. The DLT evaluation period will be six weeks. This trial will be a standard 3 by 3 dose escalation design, where three daily dose levels (20mg, 40mg, and 60mg) will be investigated.
PURPOSE:To make possible the reduction in the size of a device, the simplification of the constitution and the analysis of multiple terms by making analysis and measurement of the multiple terms by using one kind of sensitized solid phase and reagent. CONSTITUTION:A sample dispenser 22 is disposed to the stop position S4 of a reaction tube disk 21. The dispenser 22 dispenses selectively the sample from a sample cup 24 existing in the prescribed sample sucking position of a sampler 23 into U-tubes 20. A rack 23a existing in the sample dispensing position is intermittently moved toward an arrow S in synchronization with the suction operation of the dispenser 22. The sequential samples can be continuously fed to the sample dispensing position in the above-mentioned manner. The 1st reagent dispenser 25 is then disposed in the stop position S1 of the disk 21 to dispense selectively the 1st reagent 26b corresponding to the measuring item from the 1st reagents 26 of the same number as the number of the measuring items housed into the 1st reagent container 26a into the U-tubes 20. The 2nd reagent dispenser 27, the 3rd reagent dispenser 30, a carrier charger 31, a colorimeteric instrument 32, a carrier discharger 33 and a cleaner 34, etc. are further provided.
MDD patients with suicidal ideation will receive antidepressants combined with robot-assisted accelerated iTBS-1800(10 sessions per day over 5 consecutive days). This group is in order to determine the safety, tolerability and feasibility of accelerated iTBS protocol.
This 6-week series consists of a once-weekly cooking class and educational session where a group of individuals with neuromuscular disability can come together to learn about the health benefits of an anti-inflammatory diet, receive instruction on how to cook selected anti-inflammatory recipes, and experiment with various pieces of accessible kitchen equipment that may increase their meal preparation skills. This series will also allow participants to share a meal together once per week.
Daruqi is a Traditional Mongolian medicine with anti-inflammatory, anti-bacterial, and immune-regulatory effects. However, the mechanisms of its activity were unclear. In the present study, we confirmed the anti-inflammation effect of Daruqi on inflammation induced by LPS using animal models. Then, THP-1 cells treated with LPS was used as a positive control to explore the effective component of Daruqi on inflammation. We identified that Oxymatrine was the essential effector of Daruqi. Furthermore, the mechanism of Oxymatrine on inflammation was verified through proteomics analyses and validation assays. Our results demonstrated that Oxymatrine significantly reduced the levels of inflammatory cytokine, including IL-8, IL-1α, and IL-1β, in LPS induced THP-1 cells. Based on tandem mass tag -labeled quantitative proteomics, 428 differentially expressed proteins were screened, involved in TNF signaling pathway, Ferroptosis, IL-17 signaling pathway, etc. Among these differential expressed proteins (DEPs), 23 proteins were verified with parallel reaction monitoring analysis. The results showed that LPS treatment potentiated the protein level of PLEK, ACSL5 and CYBB, which could be reversed by Oxymatrine. By contrast, the protein expression of SPRYD4 and EMR2 was suppressed after LPS treatment, which could be rescued by Oxymatrine. In summary, Oxymatrine has excellent protective effects in LPS induced THP-1 cells. The five proteins, including PLEK, ACSL5, CYBB, SPRYD4 and EMR2, might serve as the targets of Oxymatrine, and as candidates regulating inflammation in future therapies.
The invention discloses a drug for treating vasculitis, pertaining to the field of Chinese herbal medicine, which is made from following raw materials according to the certain weight ratios: astragalus, Chinese Angelica, lycopus, safflower, large-headed atractylodes rhizome, scrophularia root, spatholobus stem, dried rehmannia root and plantago seed. The above raw materials are firstly put into apan, and proper water is poured inside the pan and immersed for 30 minutes and decocted. One dose of the decoction is taken in a day; each dose is divided into three parts for third-time oral taking in a day. After adopting the above formula, the invention has clinical effects of short course, fast effects and no recurrence after curing. The effect can be showed in 15 to 30 days for normal patients and the disease can be cured in 2 to 3 months. The invention totally treats 120 cases with 93 percent of cured rate and 98 percent of effective rate.
The present invention relates to a combination of at least two different substances, one of which activates the STAT1-signalling cascade and the other of which activates the TNFR1/CD95-signalling cascade in order to induce permanent growth arrest - i.e. senescence - in pre-malignant or malignant tumours or tumour cells. This induction of permanent growth arrest does not depend on cytotoxicity and does not primarily attempt to kill tumour cells, although this may occur. The induction serves to treat and/or prevent tumours by permanent growth arrest. The combination is used for therapeutic or preventative senescence induction in tumours, in which the STAT1- and TNFR1/CD95-signalling cascade can be activated and in which p16lnk4a is present. The invention transfers tumour cells and, contrary to many other therapies, the tumour stem cells, into permanent growth arrest.
The present invention relates to a double-pill product for fusing and integrating eastern and western medicine for treating gastritis with gastric acidosis symptoms. The single double-pill product is used to treat gastritis with gastric acidosis symptoms by including two components of eastern and western medicine. Accordingly, the double-pill product can enhance the therapeutic efficacy including ease of consumption and economic efficiency, eliminate the existing burdens of patients having to take two individual therapeutic agents for treatment of gastritis with gastric acidosis symptoms suffered thereby, and eliminate the financial burdens due to the rising medicine cost and low therapeutic efficacy. The therapeutic agent for treating gastritis and the gastric acidosis symptoms is a single double-pill product prepared by fusing and integrating the two components of eastern and western medicine. The two components of the double-pill product are ranitidine hydrochloride for treatment of the gastric acidosis symptoms and Banhasasim-tang which is an eastern therapeutic agent for treating gastritis. Accordingly, the double-pill product can have the above-described effects.